Skip to main content
main-content

Rheumatology

Latest articles

25-04-2022 | Rheumatology | Highlight | Article

Ancestry-specific gene expression profiles could help guide rituximab use in people with SLE

Gene expression profiles are associated with rituximab response among people of African or Asian ancestry with systemic lupus erythematosus, but not in those of European ancestry, research suggests.

22-04-2022 | Rheumatology | News | Article

Support for PsA treatment selection according to predominant clinical manifestation

Findings from a systematic review and network meta-analysis suggest that different biologics have similar efficacy for the joint manifestations of psoriatic arthritis, but IL-17A-targeted therapies or guselkumab may be the best choice for skin responses.

21-04-2022 | Rheumatology | News | Article

Maternal RA, type 1 diabetes tied to mental disorders in the next generation

Children born to mothers with autoimmune diseases have an elevated risk for mental disorders, with this risk persisting until early adulthood for those born to women with rheumatoid arthritis or type 1 diabetes, researchers report.

20-04-2022 | Rheumatology | News | Article

Bariatric surgery may reduce need for TKA in people with obesity, knee osteoarthritis

Findings from a randomized controlled trial suggest that weight-loss surgery may negate the need for total knee arthroplasty for some people with severe obesity and knee osteoarthritis.

19-04-2022 | Rheumatology | News | Article

Intramuscular glucocorticoid injection ‘considered effective’ for knee OA pain

Intramuscular glucocorticoid injection is noninferior to intra-articular injection for reducing knee pain after 8 and 24 weeks in patients with knee osteoarthritis, but may be inferior at 4 weeks, research shows.

14-04-2022 | Rheumatology | News | Article

IL-1Ra autoantibodies may contribute to MIS-C pathophysiology

Autoantibodies against IL-1Ra are present in a large proportion of patients with MIS-C, say researchers.

14-04-2022 | Rheumatology | News | Article

Glycosylation of anti-dsDNA autoantibodies linked to SLE disease activity

Among patients with systemic lupus erythematosus (SLE), glycosylation patterns of anti-double-stranded (ds)DNA IgG autoantibodies differ from those of total IgG and correlate with disease activity, suggests research published in eBioMedicine.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. 

12-04-2022 | Rheumatology | News | Article

ALEVIATE trial: Alemtuzumab may warrant further investigation for refractory vasculitis

Findings from a phase 2b trial suggest that treatment with the anti-CD52 antibody alemtuzumab may be beneficial for some patients with primary systemic vasculitis and an inadequate response to conventional therapies.

11-04-2022 | Rheumatology | News | Article

Biologic choice has minimal impact on acute coronary syndrome risk in RA

People with rheumatoid arthritis have a significantly increased risk for acute coronary syndrome that generally does not vary according to which biologic DMARD they are taking, show data from four Nordic countries.

08-04-2022 | Rheumatology | News | Article

Ultrasound-guided hip injection may benefit people with hip osteoarthritis

A single ultrasound-guided corticosteroid and local anesthetic intra-articular hip injection offers greater pain relief to people with moderate hip osteoarthritis than the best current treatment of advice and education, research suggests.

08-04-2022 | Rheumatology | News | Article

Frailty may be reversible for some RA patients

Frailty is common and associated with adverse outcomes in people with rheumatoid arthritis, but may be at least partially reversible in those with early disease, researchers report.

06-04-2022 | Rheumatology | News | Article

Baricitinib warrants further investigation for primary Sjögren’s syndrome

Findings from a phase 1/2 pilot study suggest that baricitinib may be a promising treatment option for primary Sjögren's syndrome.

05-04-2022 | Rheumatology | News | Article

Research casts doubt on benefits of TNF inhibitor, DMARD co-therapy in axSpA

Adding a conventional DMARD to tumor necrosis factor inhibitor therapy is not associated with clinically relevant improvements in drug retention or remission rates in people with axial spondyloarthritis, research suggests.

04-04-2022 | Rheumatology | News | Article

Study demonstrates negative impact of COVID-19 on rheumatology training, research

The COVID-19 pandemic has had a considerable impact on rheumatology training and research opportunities, suggest findings from an international survey study by the COVID-19 Global Rheumatology Alliance.

01-04-2022 | Rheumatology | News | Article

Trial supports tacrolimus as an alternative to cyclophosphamide for lupus nephritis

Phase 3 trial results suggest that the calcineurin inhibitor tacrolimus may represent an alternative option to cyclophosphamide for the initial treatment of lupus nephritis.

31-03-2022 | Rheumatology | News | Article

Real-world study suggests similar effectiveness of tofacitinib, TNF inhibitors

Findings from a rheumatoid arthritis registry study suggest that the JAK inhibitor tofacitinib may have comparable real-world effectiveness to TNF inhibitors.

30-03-2022 | Rheumatology | News | Article

Nurse-led education may improve safety competency in biologic initiators

A nurse-led education intervention may improve safety competency among people initiating biologics for spondyloarthritis or rheumatoid arthritis, French study findings indicate.

29-03-2022 | Rheumatology | News | Article

Baseline data may predict TNF inhibitor response in people with AS

Predictive models incorporating baseline variables can predict short-term TNF inhibitor response with moderate to high accuracy in people with active ankylosing spondylitis, study findings indicate.

28-03-2022 | Rheumatology | News | Article

BMI not a factor for TNF vs non-TNF inhibitor treatment efficacy in RA

Patients with rheumatoid arthritis may be at a greater risk for poor treatment responses if they are obese or underweight regardless of whether they are taking a tumor necrosis factor inhibitor or an alternative biologic, research indicates.

24-03-2022 | Rheumatology | News | Article

Network meta-analysis rates treatments for Kawasaki disease

Adding infliximab to standard therapy with high-dose intravenous immunoglobulin plus high-dose aspirin may decrease fever duration and prevent coronary artery lesions in children with Kawasaki disease, study findings indicate.